GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Jiuzhou Pharmaceutical Co Ltd (SHSE:603456) » Definitions » Valuation Rank

Zhejiang Jiuzhou Pharmaceutical Co (SHSE:603456) Valuation Rank


View and export this data going back to 2014. Start your Free Trial

What is Zhejiang Jiuzhou Pharmaceutical Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Zhejiang Jiuzhou Pharmaceutical Co Valuation Rank Related Terms

Thank you for viewing the detailed overview of Zhejiang Jiuzhou Pharmaceutical Co's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Jiuzhou Pharmaceutical Co (SHSE:603456) Business Description

Traded in Other Exchanges
N/A
Address
99 Waisha Road, Jiaojiang District, Taizhou, Zhejiang, CHN, 318000
Zhejiang Jiuzhou Pharmaceutical Co Ltd is a China-based pharmaceutical manufacturer. The company is primarily engaged in the manufacturing, research, development, and sale of active pharmaceutical ingredients, intermediates, asymmetric catalyst, and lithium battery materials. Its active pharmaceutical ingredient offerings include Carbamazepine, Duloxetine, Bezafibrate, Meropenem, Sulphadimethoxine Sodium, Oxcarbazepine, Amprolium, among others. The firm also provides services of new drug contract development and manufacturing organization to the international pharmaceutical giant.
Executives
Sha Yu Jie Directors, senior managers
Mei Yi Jiang Director
Li Yuan Qiang senior management
Yang Nong Gang senior management
Directors, senior managers
Huang Min Xia senior management
Wang Bin Directors, senior managers
Dai Yun You senior management
Jiang Zu Lin Directors, senior managers
Guo Zhen Rong senior management
Chen Zhi Hong Directors, senior managers
Xu Jia Jun Supervisors
Hua Li Rong Director
Lin Hui Lu senior management
Zhu Guo Liang Supervisors